NEVVI Medicare utilization intelligence
or

← back

Provider profile

TAYLOR, CHARLES M.D.

Medical Oncology · NPI 1003859679 · TULSA, OK

1
Groups
84
Codes · 2024
141,392
Disclosed services

TAYLOR, CHARLES is a Medical Oncology in TULSA, OK, a member of 1 medical group, who billed 84 distinct codes to Medicare Part B in 2024.

Groups: OKLAHOMA CANCER SPECIALISTS AND RESEARCH INSTITUTE, LLC (TULSA, OK)

Year: 2024 · 2023 · 2022 🔒 · 2021 🔒 · 2020 🔒

Provider overview · all codes · CY2024

141,392
disclosed services
84
codes billed to Medicare Part B
Prior year · CY2023 171,225 disclosed services

This provider's disclosed Medicare payments across all codes were in CY2024.

Dollars, place-of-service mix, business mix and national standing are part of the market analytics platform — built, not launched yet. Notify me at launch →

All figures are disclosed (CMS suppresses fewer-than-11-beneficiary rows) Medicare Part B fee-for-service — a subset, never complete totals; volumes are personal to this NPI, not attributed to any group. Standing is a billed-volume position among specialty peers with disclosed billing (national percentile; a provider's true standing can only be higher, never lower), not a statement about care. See Methods & Sources.

Procedures billed to Medicare Part B (2024)

Medicare Part B FFS · CY2024 · as published by CMS
This provider's Medicare volumes — services, beneficiary-episodes, and charges — are part of the market analytics platform — built, not launched yet. Notify me at launch →
CodeDescription Services Beneficiary-episodes Avg charge Avg Medicare payment
J1439 Injection, ferric carboxymaltose, 1 mg
Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml
J9271 Injection, pembrolizumab, 1 mg
J1627 Injection, granisetron, extended-release, 0.1 mg
J9299 Injection, nivolumab, 1 mg
J9263 Injection, oxaliplatin, 0.5 mg
J9267 Injection, paclitaxel, 1 mg
J9144 Injection, daratumumab, 10 mg and hyaluronidase-fihj
J1453 Injection, fosaprepitant, 1 mg
J9025 Injection, azacitidine, 1 mg
J0185 Injection, aprepitant, 1 mg
J1434 Injection, fosaprepitant (focinvez), 1 mg
J0881 Injection, darbepoetin alfa, 1 microgram (non-esrd use)
Q5126 Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg
J1100 Injection, dexamethasone sodium phosphate, 1 mg
J1449 Injection, eflapegrastim-xnst, 0.1 mg
J1930 Injection, lanreotide, 1 mg
J1569 Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg
J9041 Injection, bortezomib, 0.1 mg
Q5123 Injection, rituximab-arrx, biosimilar, (riabni), 10 mg
J0897 Injection, denosumab, 1 mg
85025 Complete blood cell count (red cells, white blood cell, platelets), automated test and automated differential white blood cell count
36415 Insertion of needle into vein for collection of blood sample
80053 Blood test, comprehensive group of blood chemicals
83735 Magnesium level
83615 Lactate dehydrogenase (enzyme) level
84100 Phosphate level
84550 Uric acid level, blood
99214 Established patient office or other outpatient visit with moderate level of decision making, if using time, 30 minutes or more
J0461 Injection, atropine sulfate, 0.01 mg
J0640 Injection, leucovorin calcium, per 50 mg
J0885 Injection, epoetin alfa, (for non-esrd use), 1000 units
J2469 Injection, palonosetron hcl, 25 mcg
J9190 Injection, fluorouracil, 500 mg
96367 Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less
96413 Administration of chemotherapy into vein, 1 hour or less
J9045 Injection, carboplatin, 50 mg
J9206 Injection, irinotecan, 20 mg
A9573 Injection, gadopiclenol, 1 ml
96372 Injection of drug or substance under skin or into muscle
82784 Gammaglobulin (immune system protein) measurement
J9196 Injection, gemcitabine hydrochloride (accord), not therapeutically equivalent to j9201, 200 mg
96415 Administration of chemotherapy into vein, each additional hour
J2405 Injection, ondansetron hydrochloride, per 1 mg
83540 Iron level
83550 Iron binding capacity
82728 Ferritin (blood protein) level
71260 Ct scan of chest with contrast
96401 Administration of non-hormonal anti-neoplastic chemotherapy under skin or into muscle
96365 Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less
J1200 Injection, diphenhydramine hcl, up to 50 mg
96375 Injection of additional new drug or substance into vein
96523 Irrigation of implanted venous access drug delivery device
A9552 Fluorodeoxyglucose f-18 fdg, diagnostic, per study dose, up to 45 millicuries
96417 Administration of additional new drug or substance into vein, 1 hour or less
74177 Ct scan of abdomen and pelvis with contrast
85055 Reticulated (young) platelet measurement
78815 Nuclear medicine study from skull base to mid-thigh with ct scan
J3489 Injection, zoledronic acid, 1 mg
J3490 Unclassified drugs
36591 Collection of blood sample from implanted device
82565 Blood creatinine level
99205 New patient office or other outpatient visit with a high level of medical decision making, if using time, 60 minutes or more
96366 Infusion into a vein for therapy, prevention, or diagnosis, each additional hour
G0498 Chemotherapy administration, intravenous infusion technique; initiation of infusion in the office/clinic setting using office/clinic pump/supplies, with continuation of the infusion in the community setting (e.g., home, domiciliary, rest home or assisted l
96402 Administration of hormonal anti-neoplastic chemotherapy under skin or into muscle
84443 Blood test, thyroid stimulating hormone (tsh)
84153 Psa (prostate specific antigen) measurement, total
96361 Infusion into a vein for hydration, each additional hour
96411 Administration of additional new drug or substance into vein using push technique
J7030 Infusion, normal saline solution , 1000 cc
96368 Infusion into a vein for therapy, prevention, or diagnosis concurrent with another infusion
82044 Urine microalbumin (protein) analysis
82378 Carcinoembryonic antigen (cea) protein level
99213 Established patient office or other outpatient visit with low level od decision making, if using time, 20 minutes or more
85045 Red blood count, automated test
99232 Subsequent hospital care with moderate levelof medical decision making, if using time, at least 35 minutes
J3475 Injection, magnesium sulfate, per 500 mg
J3420 Injection, vitamin b-12 cyanocobalamin, up to 1000 mcg
70553 Mri scan of brain before and after contrast
99223 Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes
78306 Nuclear medicine study of bone and/or joint whole body
99222 Initial hospital care with straightforward or low-level medical decision making, if using time, at least 55 minutes
A9561 Technetium tc-99m oxidronate, diagnostic, per study dose, up to 30 millicuries

These are this provider's own Medicare Part B fee-for-service volumes (CMS public data). CMS suppresses rows with fewer than 11 beneficiaries, so low-volume codes may be missing entirely — absence is not zero. Beneficiary-episodes count CMS's per-setting beneficiary figures, not unique patients. Average charge and average Medicare payment are weighted by service volume across office and facility settings. Volumes on this page are personal to the NPI and are not attributed to any physician group. See Methods & Sources.